flipper44
1 minute ago
Your position demonstrates a failure to recognize the potential monetary value for a new cancer treating paradigm, post initial marketing license and hence proof of concept, that is at once safe, efficacious, easily combined and enhanced with checkpoint inhibitors, csf1r, poly-iclc and other adjuvan
ORCA
4 minutes ago
VDRM.0047.TREMENDOUS NEWS OUT.ViaDerma, Inc. Reports Strong Financial Results for Q2 2024, Achieving Positive Net Income and Significant Cash Flow Growth
Press Release | 10/03/2024
LOS ANGELES, Oct. 03, 2024 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Pink: VDRM), an innovator in transderm